Pioglitazone as a Treatment for Lipid and Glucose Abnormalities In Patients With Schizophrenia

This study has been completed.
Sponsor:
Information provided by:
Nathan Kline Institute for Psychiatric Research
ClinicalTrials.gov Identifier:
NCT00231894
First received: October 3, 2005
Last updated: July 22, 2011
Last verified: April 2010
  Purpose

This is a study with an approved drug for treating type 2 diabetes, for its effects on treating glucose and lipid abnormalities in patients being treated with olanzapine and clozapine, and comparison of effects of this drug with another treatment lifestyle modification. Patients who meet inclusion criteria will be treated with pioglitazone for 12 weeks. They will be evaluated for fasting glucose and lipids, glucose-tolerance tests, and neurocognitive battery and tests of verbal memory at baseline and during treatment with pioglitazone.


Condition Intervention
Diabetes
Schizophrenia
Insulin Resistance
Cognitive Impairment
Drug: Pioglitazone
Behavioral: Life style diet group
Other: placebo

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Pioglitazone as a Treatment for Lipid and Glucose Abnormalities In Patients With Schizophrenia Treated With Antipsychotic Medication And Potential Effects on Cognitive Function

Resource links provided by NLM:


Further study details as provided by Nathan Kline Institute for Psychiatric Research:

Primary Outcome Measures:
  • serum triglycerides [ Time Frame: pre tereatment and during 3 months of treatment ] [ Designated as safety issue: No ]
  • HDL [ Time Frame: pretreatment and during 3 months of treatment ] [ Designated as safety issue: No ]
  • atherosclerotic risk ratios (total cholesterol/HDL and triglycerides/HDL) [ Time Frame: pretreatment and during 3 months of treatment ] [ Designated as safety issue: No ]
  • serum glucose [ Time Frame: pretreatment and during 3 months of drug treatment ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • immediate and delayed verbal memory performance [ Time Frame: preteatment and during 3 months of treatment ] [ Designated as safety issue: No ]
  • memory improvement during GTT glucose test, on paired words and short story of the RANDT Memory Scale [ Time Frame: pre-treatment and during 3 months of treatment ] [ Designated as safety issue: No ]

Estimated Enrollment: 40
Study Start Date: May 2005
Study Completion Date: January 2010
Primary Completion Date: January 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
pioglitazone
Drug: Pioglitazone
pioglitazone 15-45 mg/day
Other Name: Actos
Behavioral: Life style diet group
life style diet education group 1x/week
Placebo Comparator: 2
placebo
Behavioral: Life style diet group
life style diet education group 1x/week
Other: placebo
placebo comparator

Detailed Description:

The aim of this study is to investigate the effects of pioglitazone added to weight-lifestyle intervention vs. placebo plus lifestyle intervention on reversing or reducing impaired or abnormal triglycerides, HDL and glucose metabolism in schizophrenics treated with clozapine or olanzapine. Another aim is to examine the effects of impaired glucose metabolism on verbal memory and other cognitive function in schizophrenic patients treated with these medications and the relationship to improvements in impaired glucose metabolism to impairments in cognitive function. Clozapine and olanzapine, two second generation antipsychotics effective for treating schizophrenia and bipolar disorders, have been reported to be associated with increased incidence of diabetic type metabolic abnormalities, decreases in insulin sensitivity, and abnormal glucose tolerance tests. This can lead to the development of type 2 diabetes and also abnormal lipid metabolic levels which can lead to atherosclerotic changes and increased risk of cardiovascular disease and other diabetes related complications. Drug treatments which could reduce or correct these diabetic metabolic changes would permit many patients to continue to receive the benefits of these antipsychotic medications with reduced drug-induced comorbidity. Previous research using non-psychotic subjects has shown that diabetes and impaired glucose tolerance are associated with cognitive impairments, especially in verbal memory, and provides a rationale for testing whether corrections of impaired glucose metabolism are associated with cognitive improvements in schizophrenic patients.

  Eligibility

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patients will be males or females, 18-70 yrs of age, with a diagnosis of schizophrenia or schizoaffective disorder, and currently being treated with olanzapine or clozapine.
  2. Patients will have evidence of:

    1. glucose levels indicating at least impaired fasting glucose: fasting glucose 100 mg/dL or 2 hr glucose tolerance test 140 mg/dL, or current treatment with oral antidiabetic drugs with history of hyperglycemia;
    2. Triglyceride levels > 150 mg/dL and/or HDL levels < 40 mg/dL

Exclusion Criteria:

  1. Diabetes mellitus, type 1
  2. Recent diabetic ketoacidosis;
  3. Patients not currently treated with oral antidiabetic drugs but fasting is glucose 140 mg/dL [WHO criteria] on repeat testing in last three months, or random blood glucose >200 mg/dL plus 2 hr glucose on GTT >200 mg/dL; (these patients may need more immediate treatment with antidiabetic drugs and it is less certain if weight-lifestyle treatment would be effective in treating such high glucose levels);
  4. Patients with active liver disease with clinical abnormalities which need current treatment, or liver enzymes (Alt) 3 times upper limit for normal values in chart records in last year, or patients who are recorded as positive for hepatitis C;
  5. Congestive heart failure (Class III or IV cardiac status) or history of MI in medical record (because pioglitazone can increase blood volume slightly);
  6. Hematocrit greater than 10% below normal (hematocrit may be decreased 2 to 4% due to increased plasma volume);
  7. Female patients on current oral contraceptives (because pioglitazone may interfere with effects of some oral contraceptives);
  8. Patients taking ketoconazole,
  9. Patients who have started on atorvastatin or gemfibrozil in the past 2 months or have had a dose increase in atorvastatin in the last month (since these drugs can also lower triglycerides and raise HDL, recent start of therapy with these drugs could be a confound).
  10. Patients are not concomitantly treated with aripiprazole or ziprasidone.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00231894

Locations
United States, New York
Manhattan Psychiatric Center
New York, New York, United States, 10035
Sponsors and Collaborators
Nathan Kline Institute for Psychiatric Research
Investigators
Principal Investigator: Robert C Smith, MD PhD NYU School of Medicine & Manhattan Psychiatric Center
  More Information

No publications provided

Responsible Party: Robert C. Smith MD, PhD, Manattan Psychiatric Center, NYU Medical School
ClinicalTrials.gov Identifier: NCT00231894     History of Changes
Other Study ID Numbers: 04T-584 Stanley Foundation, 04T-584
Study First Received: October 3, 2005
Last Updated: July 22, 2011
Health Authority: United States: Institutional Review Board

Keywords provided by Nathan Kline Institute for Psychiatric Research:
atypical antipsychotics
hyperglycemia
triglycerides
HDL
cholesterol
insulin resistance
schizophrenia
verbal memory

Additional relevant MeSH terms:
Congenital Abnormalities
Insulin Resistance
Schizophrenia
Cognition Disorders
Hyperinsulinism
Glucose Metabolism Disorders
Metabolic Diseases
Schizophrenia and Disorders with Psychotic Features
Mental Disorders
Delirium, Dementia, Amnestic, Cognitive Disorders
Antipsychotic Agents
Pioglitazone
Tranquilizing Agents
Central Nervous System Depressants
Physiological Effects of Drugs
Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses
Psychotropic Drugs
Hypoglycemic Agents

ClinicalTrials.gov processed this record on July 23, 2014